Savient Pharmaceuticals (SVNT -11%) takes a hit today after its Q1 results missed estimates....


Savient Pharmaceuticals (SVNT -11%) takes a hit today after its Q1 results missed estimates. Total revenue actually jumped nearly 170% Y/Y, but bottom line margins were hit as expenses increased sharply. Much of the increase in expenses had to do with the commercialization and marketing of its new gout drug Krystexxa.
From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs